Kyongbo Pharmaceutical Co Ltd (214390) — Cash Flow-to-Debt Ratio
Kyongbo Pharmaceutical Co Ltd (214390) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of ₩4.51 Billion could theoretically repay 0% of its total liabilities (₩171.21 Billion) in one year. Explore Kyongbo Pharmaceutical Co Ltd (214390) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kyongbo Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Kyongbo Pharmaceutical Co Ltd across 11 annual periods. Also explore 214390 total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Kyongbo Pharmaceutical Co Ltd (2014–2024)
Year-by-year debt coverage analysis for Kyongbo Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Kyongbo Pharmaceutical Co Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.00x | ₩149.12 Million | ₩137.73 Billion | ▼ -97.3% |
| 2023 | 0.04x | ₩4.84 Billion | ₩121.92 Billion | ▼ -62.0% |
| 2022 | 0.10x | ₩10.13 Billion | ₩96.84 Billion | ▼ -46.9% |
| 2021 | 0.20x | ₩17.97 Billion | ₩91.28 Billion | ▼ -8.0% |
| 2020 | 0.21x | ₩20.80 Billion | ₩97.18 Billion | ▼ -19.8% |
| 2019 | 0.27x | ₩23.67 Billion | ₩88.65 Billion | ▲ +1803.2% |
| 2018 | -0.02x | ₩-1.14 Billion | ₩72.61 Billion | ▼ -103.8% |
| 2017 | 0.41x | ₩25.81 Billion | ₩63.36 Billion | ▲ +19.5% |
| 2016 | 0.34x | ₩25.33 Billion | ₩74.33 Billion | ▲ +484.0% |
| 2015 | 0.06x | ₩4.24 Billion | ₩72.67 Billion | ▼ -63.7% |
| 2014 | 0.16x | ₩16.04 Billion | ₩99.70 Billion | — |